Bristol-Myers Squibb Company [BMY] Is Currently -2.50 below its 200 Period Moving Avg: What Does This Mean?


Bristol-Myers Squibb Company [NYSE: BMY] loss -2.50% on the last trading session, reaching $75.27 price per share at the time. The company report on April 29, 2022 that R&D Facility Building in the UK Exemplifies Sustainability Innovation.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


This Earth Month, learn how a Bristol Myers Squibb facility in the UK has transformed its reputation.

Bristol-Myers Squibb Company represents 2.15 billion in outstanding shares, while the company has a total market value of $164.07 billion with the latest information. BMY stock price has been found in the range of $73.35 to $76.01.

If compared to the average trading volume of 15.24M shares, BMY reached a trading volume of 26445442 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Bristol-Myers Squibb Company [BMY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $77.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on April 06, 2022. While these analysts kept the previous recommendation, Goldman raised their target price to Buy. The new note on the price target was released on December 17, 2021, representing the official price target for Bristol-Myers Squibb Company stock. Previously, the target price had yet another raise to $58, while Wells Fargo analysts kept a Equal Weight rating on BMY stock.

The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.51, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.54. The Price to Book ratio for the last quarter was 5.11, with the Price to Cash per share for the same quarter was set at 6.87. Price to Free Cash Flow for BMY in the course of the last twelve months was 15.38 with Quick ratio for the last quarter at 1.20.

Trading performance analysis for BMY stock

Bristol-Myers Squibb Company [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.63. With this latest performance, BMY shares gained by 2.10% in over the last four-week period, additionally plugging by 31.75% over the last 6 months – not to mention a rise of 20.59% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 51.76, with the RSI for the last a single of trading hit 45.93, and the three-weeks RSI is set at 55.75 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 72.37, while it was recorded at 75.98 for the last single week of trading, and 64.92 for the last 200 days.

Bristol-Myers Squibb Company [BMY]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +20.57 and a Gross Margin at +57.69. Bristol-Myers Squibb Company’s Net Margin is presently recorded at +15.08.

Return on Equity for this stock inclined to 18.96, with Return on Assets sitting at 6.14.

Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.30.

Bristol-Myers Squibb Company [BMY]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 4.97%.

An analysis of insider ownership at Bristol-Myers Squibb Company [BMY]

There are presently around $120,380 million, or 77.60% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 199,834,483, which is approximately 0.454% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 169,226,707 shares of the stock with an approximate value of $12.74 billion in BMY stocks shares; and STATE STREET CORP, currently with $7.12 billion in BMY stock with ownership of nearly 2.182% of the company’s market capitalization.

Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,175 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 80,591,530 shares. Additionally, 1,136 investors decreased positions by around 113,519,503 shares, while 270 investors held positions by with 1,405,195,131 shares. The mentioned changes placed institutional holdings at 1,599,306,164 shares, according to the latest SEC report filing. BMY stock had 243 new institutional investments in for a total of 11,256,871 shares, while 137 institutional investors sold positions of 9,743,445 shares during the same period.